

# FORMATO EUROPEO PER IL CURRICULUM VITAE



## INFORMAZIONI PERSONALI

Nome

**SHIGEKI KUSAMURA**

E-mail

[shigeki.kusamura@istitutotumori.mi.it](mailto:shigeki.kusamura@istitutotumori.mi.it)

Cittadinanza

ITALIANA

Data di nascita

22/12/1970

## ESPERIENZA LAVORATIVA

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

### **1 AGOSTO 2020 AD OGGI**

Dott. Marcello Deraco, Struttura complessa Chirurgia Colon-rettale, Struttura Semplice Tumori Peritoneali, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Dirigente Medico Contratto a Tempo Determinato

Chirurgo; specialista nel trattamento chirurgico dei pazienti affetti da Tumori Peritoneali con la tecnica di **Peritonectomia e HIPEC (chemioipertermia intraperitoneale)**. Gestione dei progetti di ricerca nell'ambito della chirurgia peritoneale.

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

### **1 GENNAIO 2011 AL 31 LUGLIO 2020**

Dott. Marcello Deraco, Struttura complessa Chirurgia Colon-rettale, Struttura Semplice Tumori Peritoneali, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Contratto di Collaborazione Professionale

Chirurgo; specialista nel trattamento chirurgico dei pazienti affetti da Tumori Peritoneali con la tecnica di **Peritonectomia e HIPEC (chemioipertermia intraperitoneale)**. Gestione dei progetti di ricerca nell'ambito della chirurgia peritoneale.

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

### **2002 A 2006**

Dott. Marcello Deraco, Dipartimento di chirurgia, Programma Tumori Peritoneali, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Cococo

Ricercatore nell'ambito della chirurgia dei Tumori Peritoneali

## ISTRUZIONE E FORMAZIONE

- Date (da – a)
- Nome e tipo d'istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita

### **Gennaio 2020**

**Ministero dell'istruzione, dell'università e della ricerca (MIUR)**

**Abilitazione Scientifica Nazionale**

**Professore di Prima e Seconda Fascia in Chirurgia Generale (06/C1).**

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
  - Principali materie / abilità professionali oggetto dello studio
  - Qualifica conseguita
- Livello nella classificazione nazionale (se pertinente)

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
  - Principali materie / abilità professionali oggetto dello studio
  - Qualifica conseguita

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
  - Principali materie / abilità professionali oggetto dello studio
  - Qualifica conseguita

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
  - Principali materie / abilità professionali oggetto dello studio
  - Qualifica conseguita

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
  - Principali materie / abilità professionali oggetto dello studio
  - Qualifica conseguita

**MADRELINGUA**  
**ALTRE LINGUE**

**2005 a 2010**

Specializzando in Chirurgia, Dipartimento di Chirurgia, Ospedale San Raffaele HSR, via Olgettina 60, cap 20132, Milano, Italia  
Chirurgia Gastroenterologica

Specialista in Chirurgia Gastroenterologica.

**2002 a 2006**

Departamento de Obstetricia e Ginecologia, Faculdade de Ciências Médicas , Universidade Estadual de Campinas, Sao Paulo, Brasil.

Dottorato di ricerca. Titolo della tesi: Ruolo della chirurgia di citoriduzione e chemioipertermia intraperitoneale nel trattamento del cancro ovarico avanzato.

PhD.

**2005** (Decreto 26 aprile 2005 Gazzetta Ufficiale della Repubblica italiana)

Ministero della Salute della Repubblica Italiana

Il titolo di “medico” rilasciato in data 15 dicembre 1995 dall’Universidade Estadual de Campinas, Sao Paulo Brasile è riconosciuto quale titolo abilitante per l’esercizio in Italia della professione di medico chirurgo.

Medico chirurgo.

**1996 a 1998**

Specializzando presso “Departamento de Obstetricia e Ginecologia, Faculdade de Ciências Médicas , Universidade Estadual de Campinas, Sao Paulo, Brasil”

Ginecologia e Ostetricia e Oncologia Ginecologica

Specialista in Ginecologia e Ostetricia.

**1990 a 1995**

Studente di Medicina presso “Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Sao Paulo, Brasil”

Medicina

Medico Chirurgo.

**GIAPPONESE**

**ITALIANO (B2), PORTOGHESE (C2), INGLESE (C1)**

## Ulteriori Informazioni

Responsabilità scientifica per progetti di ricerca internazionali e nazionali, ammessi al finanziamento sulla base di bandi competitivi che prevedano la revisione tra pari

2015-2020

Principal Investigator del progetto di ricerca "**International Registry on Peritoneal Mesothelioma: a Peritoneal Surface Oncology Group International (PSOGI) study**". Il protocollo è stato approvato dal CE della Fondazione IRCCS Istituto Nazionale dei Tumori Milano e il reclutamento dei pazienti è in corso. Pubblicazioni correlati al progetto: doi: 10.1016/j.ejso.2018.10.065, doi: 10.1245/s10434-017-6293-5.

2020

Principal Investigator del progetto di ricerca "**Peritoneal Surface Oncology Group International (PSOGI) Registry on Pseudomyxoma Peritonei**" Il protocollo è stato approvato dal CE della Fondazione IRCCS Istituto Nazionale dei Tumori Milano.

2018

Vincitore del bando ricerca promossa dalla Direzione scientifica Fondazione Istituto Nazionale dei Tumori di Milano. Progetto: "**Aminolevulinic acid-mediated photodynamic technique in patients with diffuse malignant peritoneal mesothelioma and peritoneal metastasis from colorectal cancer: results of a phase I and biological study**". L'importo: 40.000,00 euro.

2017-2020

Co-investigatore del progetto di ricerca traslazionale "**PMP: Optimizing Treatment by Exploring the Connections between Oncogene Mutations and Inflammation**" finanziato dall'AIRC

2013

Vincitore del bando AIRC (Associazione Italiana per la Ricerca contro il Cancro) per finanziamento del progetto di ricerca "**Effects of high Intra-abdominal pressure on tissue diffusion and pharmacokinetics of cisplatin during HIPEC**". L'importo: 135.000,00 euro.

2012-2015

Co-investigatore del progetto di ricerca traslazionale "**Optimize Outcomes by the Integration of new Prognostic Factors and Potential Therapeutic Targets in a Individualized Treatment based on Molecular Characterization and Chemosensitivity Profile on Primary Cultures**" finanziato dalla Ricerca Finalizzata 2009, Ministero della Salute.

Direzione o partecipazione alle attività di un gruppo di ricerca o insegnamento caratterizzato da collaborazioni a livello nazionale o internazionale

2018 a 2019

Membro del comitato esecutivo del progetto **COST CA17101 Euro PMP**, un progetto finalizzato alla creazione di cooperazione interspedaliera a livello della comunità europea per lo sviluppo della ricerca e ottimizzazione della gestione clinica dei pazienti affetti da una neoplasia peritoneale quale il pseudomyxoma peritonei.

2015 a 2019

Segretario scientifico e insegnante dell'**ESPSO** (European School of Peritoneal Surface Oncology- Scuola Europea della Chirurgia Peritoneale). Tale progetto ha la missione di diffondere e insegnare la tecnica e le conoscenze riguardanti la chirurgia peritoneale ai chirurghi oncologici in ambito internazionale.

2018 a 2019

Membro dell'**Oncoteam Carcinosi Peritoneali** affiliata alla **SICO** (Società Italiana di Chirurgia Oncologica).

2018

Membro del comitato coordinatore del "**Consensus Statement for Pseudomyxoma Peritonei and Peritoneal Mesothelioma**". Tale iniziativa, sponsorizzata dal PSOGI (Peritoneal Surface Oncology International) ha definito le linee guida e raccomandazioni internazionali del trattamento del pseudomyxoma peritonei e mesotelioma peritoneale

Conseguimento di premi e riconoscimenti per l'attività

Pagina 3 - Curriculum vitae di  
[ Kusamura Shigeki ]

25/11/2016

Membro onorario della Società Brasileira di Chirurgia Oncologica (Sociedade Brasileira di

Per ulteriori informazioni:  
[www.cedefop.eu.int/transparency](http://www.cedefop.eu.int/transparency)  
[www.europa.eu.int/comm/education/index\\_it.html](http://www.europa.eu.int/comm/education/index_it.html)  
[www.eurescv-search.com](http://www.eurescv-search.com)

scientific, inclusa l'affiliazione ad  
accademie di riconosciuto prestigio  
nel settore

Cirurgia Oncologica – SBCO).

6 novembre 2014

Invitato alla Celebrazione della **Giornata Nazionale per la Ricerca sul Cancro**, svolta al Palazzo del Quirinale, alla presenza del Presidente della Repubblica, Giorgio Napolitano, nel corso della quale hanno preso la parola il Presidente dell'Associazione Italiana per la Ricerca sul Cancro, Giuseppe Torrani, il Direttore dell'Istituto di Genetica presso il Comprehensive Cancer Center del Ohio State University, Carlo Croce, il Direttore Scientifico dell'Istituto Europeo di Oncologia, Umberto Veronesi, Eleonora Guzzi, testimonial AIRC, e il Ministro della Salute, Beatrice Lorenzin.

1998 a 2019

Membro onorario della **SITILo** (Società Italiana di Terapie Integrate Locoregionali).

2006

Comitato organizzativo e coordinatore scientifico del Congresso Internazionale sulla Chirurgia Peritoneale organizzata dal **PSOGI** (Peritoneal Surface Oncology International) . Milano. Fondazione IRCCS Istituto Nazionale dei Tumori di Milano.

Partecipazione a congressi nazionali  
o internazionali come relatore

19/06/08 a 21/06/08

Speaker at XXXI Congresso Nazionale SICO, Forlì, Italia.

15/05/09 a 16/05/09

speaker at the SICO course "Peritonectomia e chemioipertermia peritoneale nelle carcinosi - pianificazione del trattamento e del rischio operatorio", held in Bertinoro, Italy.

19/05/09 a 20/05/09

Speaker at "XI Congresso Nazionale SITILo (Società italiana di Terapie Integrate Locoregionali): Le terapie locoregionali nella pratica clinica".

08/09/10 a 10/09/10

Faculty member at 7th International World Congress on Peritoneal Surface Malignancies held in Uppsala in 2010. Participation as moderator of a session.

12/12/10 a 14/12/10

Speaker at XII Congresso Nazionale SITILo (società italiana di terapie integrate locoregionali): Terapie locoregionali in oncologia dal laboratorio alla pratica clinica, held in Bari, Italy.

11/05/12 a 11/05/12

Speaker at 3° CONVEGNO CONGIUNTO DELLE SOCIETA' LOMBARDA E TRIVENETA DI CHIRURGIA. "L'innovazione nell'organizzazione e nell'assistenza in chirurgia; Carcinosi peritoneale da ca colo rettale: citoriduzione, hipec e chemioterapia sistemica. the event was held in Desenzano 2012.

31/10/12 a 02/11/12

Faculty member at 8th International World Congress on Peritoneal Surface Malignancies held in Berlin in 2012. Participation as moderator of a session (page 11) and speaker (see attached program page 24).

16/02/13 a 18/02/13

Speaker at 8th International Symposium on Regional Cancer Therapies, Indian Wells, California, USA.

01/03/13 a 01/03/13

Speaker at the congress "La patologia neoplastica del peritoneo: dalla diagnosi al trattamento integrato" held in Istituto clinico Humanitas.

15/02/14 a 17/02/14

Speaker at 9th International Symposium on Regional Cancer Therapies, Steamboat Springs, Colorado, USA.

04/04/14 a 04/04/14

speaker at "Giornata su"il Cancro gastrico localmente avanzato"held in the University hospital of Perugia.

09/10/14 a 11/10/14

Invited speaker at 9th International World Congress on Peritoneal Surface Malignancies held in Amsterdam in 2014. Oral presentation "Nomogram to predict prognosis in Pseudomyxoma Peritonei: a PSOGI multicenter study".

14/02/15 a 16/02/15

Speaker at 10th International Symposium on Regional Cancer Therapies, Clear Water Beach, Florida, USA.

11/06/15 a 12/06/15

Speaker and Chairperson at the Congress "Peritoneal Metastases from Colorectal and Ovarian Cancer: the turning point? , Humanitas hospital, Rozzano-Milano, Italy.

17/11/15 a 17/11/15

Speaker and Organizer as scientific secretary of the congress: " Tumori Peritoneali: 20 anni di esperienza dell'Isstituto Nazionale dei Tumori di Milano".

13/02/16 a 15/02/16

Speaker at 11th International Symposium on Regional Cancer Therapies, Chandler, Arizona, USA.

22/09/16 a 22/09/16

Faculty member at XXXIV ICHS Annual Congress, & 4th International Oncotherm Congress, Pesaro, Italy.

17/11/16 a 19/11/16

Faculty member at 10th International World Congress on Peritoneal Surface Malignancies held in Washington in 2016. Participation as a speaker and moderator of a session (see page 10 attached program).

02/09/17 a 03/09/17

Speaker at "Jornada de Cirurgia Oncologica held at Santa Casa Misericordia De Porto Alegre, Federal University of Porto Alegre, Rio Grande do Sul, Brasil.

23/03/18 a 23/03/18

Speaker at "3rd International course in endovascular oncology "held in Pesaro.

18/05/18 a 19/05/18

Speaker at 1st Spring Meeting of SICO ONCOTEAMS held in Polignano al Mare, Bari, Italy, 2018.

09/09/18 a 11/09/18

Faculty member at 11th International World Congress on Peritoneal Surface Malignancies held in Paris in 2018. Participation as speaker in four sessions (pages 11, 15, 16, 19 of attached program).

14/10/18 a 18/10/18

Faculty member of Congresso Congiunto delle Società Scientifiche Italiane di Chirurgia, 14 to 18th of october 2018, Rome.

19/04/2019 a 21/04/2019

Faculty at 3rd International course workshop & conference on Peritoneal Surface Malignancies, year in review: gynecologic oncology and debates on colorectal cancer. Organizzato da Indian Society of Peritoneal Surface Malignancies (ISPSM) e ESSO. Sede dell'evento:Tata Memorial Hospital in Mumbai. Esecuzione di citoriduzione e hipec dimostrativa.

## PUBBLICAZIONI SCIENTIFICHE

1: **Kusamura S**, Kepenekian V, Villeneuve L, Lurvink RJ, Govaerts K, De Hingh IHJT, Moran BJ, Van der Speeten K, Deraco M, Glehen O; PSOGI. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. *Eur J Surg Oncol.* 2020 Mar 12:S0748-7983(20)30113-X. doi: 10.1016/j.ejso.2020.02.011. Epub ahead of print. PMID: 32209311.

2: Govaerts K, Lurvink RJ, De Hingh IHJT, Van der Speeten K, Villeneuve L, **Kusamura S**, Kepenekian V, Deraco M, Glehen O, Moran BJ; PSOGI. Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. *Eur J Surg Oncol.* 2020 Feb 28:S0748-7983(20)30114-1. doi: 10.1016/j.ejso.2020.02.012. Epub ahead of print. PMID: 32199769.

3: Reis ACV, **Kusamura S** (second first author), Azmi N, Fumagalli L, Piccioni F, Valenza F, Baratti D, Guaglio M, Cavalleri A, Garrone G, Barretta F, Deraco M. Hemodynamic and respiratory implications of high intra-abdominal pressure during HIPEC. *Eur J Surg Oncol.* 2020 Feb 19:S0748-7983(20)30108-6. doi: 10.1016/j.ejso.2020.02.006. Epub ahead of print. PMID: 32147425.

4: Baratti D, Sammartino P, **Kusamura S**, Deraco M; Peritoneal Surface Malignancy Onco-team of the Italian Society of Surgical Oncology (SICO), Ansaloni L, Asero S, Baiocchi G, Bagnoli P, Cavaliere D, Framarini M, Ciocchi R, Coccolini F, Decian F, Delrio P, Sassaroli C, De Simone M, Robella M, Vaira M, Di Giorgio A, Fagotti A, Lorusso D, Federici O, Fiorentini G, Fambrini M, Scaringi S, Garofalo A, Valle M, Gelmini R, Cabry F, Causero N, Sorrentino L, Graziosi L, Guaglio M, Montenovolo M, Bartolini V, Lippolis PV, Macri A, Pasqual EM, Roviello F, Marrelli D, Orsenigo E, Sommariva A. Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases. *Eur J Surg Oncol.* 2020 May;46(5):737-739. doi: 10.1016/j.ejso.2020.02.010. Epub 2020 Feb 15. PMID: 32107093.

5: Belfiore A, Busico A, Bozzi F, Brich S, Dallera E, Conca E, Capone I, Gloghini A, Volpi CC, Cabras AD, Pilotti S, Baratti D, Guaglio M, Deraco M, **Kusamura S**, Perrone F. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma. *Int J Mol Sci.* 2019 Nov 19;20(22):5817. doi: 10.3390/ijms20225817. PMID: 31752449; PMCID: PMC6888071.

6: Baratti D, **Kusamura S**, Azmi N, Guaglio M, Montenovolo M, Deraco M. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). *Ann Surg Oncol.* 2020 Jan;27(1):98-106. doi: 10.1245/s10434-019-07935-2. Epub 2019 Nov 5. PMID: 31691116.

7: Batista TP, **Kusamura S**. Comments on: Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study. *J Gynecol Oncol.* 2019 Nov;30(6):e111. doi: 10.3802/jgo.2019.30.e111. PMID: 31576696; PMCID: PMC6779613.

8: **Kusamura S**, Azmi N, Fumagalli L, Baratti D, Guaglio M, Cavalleri A, Garrone G, Battaglia L, Barretta F, Deraco M. Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intra-abdominal pressure (IAP) during HIPEC (NCT02949791). *Eur J Surg Oncol.* 2019 Jun 21:S0748-7983(19)30516-5. doi: 10.1016/j.ejso.2019.06.022. Epub ahead of print. PMID: 31262599.

9: Deraco M, Sinukumar S, Salcedo-Hernández RA, Rajendra VJ, Baratti D, Guaglio M, Nizri E, **Kusamura S**. Clinico-pathological outcomes after total peritoneal resection, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institute experience. *Eur J Surg Oncol.* 2019 Nov;45(11):2103-2108. doi: 10.1016/j.ejso.2019.06.021. Epub 2019 Jun 13. PMID: 31230982.

10: Guadagni S, Fiorentini G, Palumbo P, Masedu F, Ricevuto E, Bruera G, Deraco M, **Kusamura S**, Sarti D, Fiorentini C, Gailhofer S, Clementi M. Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: a retrospective study. *Minerva Chir.* 2019 Aug;74(4):304-312. doi: 10.23736/S0026-4733.19.07896-9. Epub 2019 May 2. PMID: 31062943.

11: Raimondi A, Corallo S, Niger M, Antista M, Randon G, Morano F, Milione M, **Kusamura S**, Baratti D, Guaglio M, Cremolini C, Marmorino F, Di Bartolomeo M, Deraco M, De Braud F, Pietrantonio F. Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. *Clin Colorectal Cancer.* 2019 Jun;18(2):e179-e190. doi: 10.1016/j.clcc.2019.03.002. Epub 2019 Apr 1. PMID: 31023524.

- 12: Lurvink RJ, Villeneuve L, Govaerts K, de Hingh IHJT, Moran BJ, Deraco M, Van der Speeten K, Glehen O, Kepenekian V, **Kusamura S**; List of PSOGI collaborators. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. *Eur J Surg Oncol*. 2019 Mar 23;S0748-7983(19)30337-3. doi: 10.1016/j.ejso.2019.03.012. Epub ahead of print. PMID: 30954350.
- 13: Sciarillo R, Wojtuszkiewicz A, El Hassouni B, Funel N, Gandellini P, Lagerweij T, Buonamici S, Blijlevens M, Zeeuw van der Laan EA, Zaffaroni N, Deraco M, **Kusamura S**, Würdinger T, Peters GJ, Molthoff CFM, Jansen G, Kaspers GJL, Cloos J, Giovannetti E. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. *EBioMedicine*. 2019 Jan;39:215-225. doi: 10.1016/j.ebiom.2018.12.025. Epub 2018 Dec 20. PMID: 30581150; PMCID: PMC6355829.
- 14: Alzahrani NA, Valle SJ, Fisher OM, Sugarbaker PH, Yonemura Y, Glehen O, Goere D, Honore C, Brigand C, de Hingh I, Verwaal VJ, Deraco M, Baratti D, **Kusamura S**, Pocard M, Piso P, Maerz L, Marchal F, Moran B, Levine EA, Dumont F, Pezet D, Abboud K, Kozman MA, Liauw W, Morris DL; Peritoneal Surface Oncology Group International (PSOGI) and Big-RENAPE groups. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience. *J Surg Oncol*. 2019 Mar;119(3):336-346. doi: 10.1002/jso.25277. Epub 2018 Dec 16. PMID: 30554404.
- 15: Deraco M, Nizri E, Glehen O, Baratti D, Tuech JJ, Bereder JM, Kepenekian V, **Kusamura S**, Goere D. Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry. *Eur J Surg Oncol*. 2019 Mar;45(3):371-375. doi: 10.1016/j.ejso.2018.10.065. Epub 2018 Oct 19. PMID: 30473172.
- 16: Nizri E, **Kusamura S**, Deraco M. Blood Transfusion in Cytoreductive Surgery: Better Not at All. *Ann Surg Oncol*. 2018 Dec;25(Suppl 3):711-712. doi: 10.1245/s10434-018-6814-x. Epub 2018 Oct 1. PMID: 30276643.
- 17: Guadagni S, Clementi M, Bencivenga M, **Kusamura S**, Fiorentini C, Masedu F. Palliation with a multimodality treatment including hypoxic pelvic perfusion for unresectable recurrent rectal cancer: outcomes based on a retrospective study. *Updates Surg*. 2018 Dec;70(4):441-447. doi: 10.1007/s13304-018-0592-7. Epub 2018 Sep 6. PMID: 30191532.
- 18: Baratti D, **Kusamura S**, Iusco D, Cotsoglou C, Guaglio M, Battaglia L, Virzi S, Mazzaferro V, Deraco M. Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases? *Dis Colon Rectum*. 2018 Sep;61(9):1026-1034. doi: 10.1097/DCR.0000000000001156. PMID: 30086051.
- 19: Nizri E, **Kusamura S**, Fallabrino G, Guaglio M, Baratti D, Deraco M. Dose-Dependent Effect of Red Blood Cells Transfusion on Perioperative and Long-Term Outcomes in Peritoneal Surface Malignancies Treated with Cytoreduction and HIPEC. *Ann Surg Oncol*. 2018 Oct;25(11):3264-3270. doi: 10.1245/s10434-018-6630-3. Epub 2018 Jul 26. PMID: 30051371.
- 20: **Kusamura S**, González-Moreno S, Nizri E, Baratti D, Guadagni S, Guaglio M, Battaglia L, Deraco M. Learning Curve, Training Program, and Monitorization of Surgical Performance of Peritoneal Surface Malignancies Centers. *Surg Oncol Clin N Am*. 2018 Jul;27(3):507-517. doi: 10.1016/j.soc.2018.02.009. PMID: 29935686.
- 21: Nizri E, Baratti D, Guaglio M, Sinukumar S, Cabras A, **Kusamura S**, Deraco M. Multicystic mesothelioma: Operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy. *Eur J Surg Oncol*. 2018 Jul;44(7):1100-1104. doi: 10.1016/j.ejso.2018.03.004. Epub 2018 Mar 14. PMID: 29703622.
- 22: Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C, Guaglio M, **Kusamura S**, Deraco M. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. *Eur J Surg Oncol*. 2018 Jun;44(6):792-798. doi: 10.1016/j.ejso.2018.02.010. Epub 2018 Feb 17. PMID: 29503128.
- 23: Liu Y, Yonemura Y, Levine EA, Glehen O, Goere D, Elias D, Morris DL, Sugarbaker PH, Tuech JJ, Cashin P, Spiliotis JD, de Hingh I, Ceelen W, Baumgartner JM, Piso P, Katayama K, Deraco M, **Kusamura S**, Pocard M, Quenet F, Fushita S; BIG-RENAPE Group. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience. *Ann Surg Oncol*. 2018 May;25(5):1184-1192. doi: 10.1245/s10434-018-6369-x. Epub 2018 Feb 26. PMID: 29484565; PMCID: PMC5891561.
- 24: Guaglio M, Sinukumar S, **Kusamura S**, Milione M, Pietrantonio F, Battaglia L, Guadagni S, Baratti D, Deraco M. Correction to: Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series. *Ann Surg Oncol*. 2018 Dec;25(Suppl 3):987. doi: 10.1245/s10434-018-6341-9. Erratum for: *Ann Surg Oncol*. 2018 Apr;25(4):878-884. PMID: 29352430.
- 25: Guaglio M, Sinukumar S, **Kusamura S**, Milione M, Pietrantonio F, Battaglia L, Guadagni S, Baratti D, Deraco M. Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series. *Ann Surg Oncol*. 2018 Apr;25(4):878-884. doi: 10.1245/s10434-018-6341-9. Epub 2017 Dec 21. Erratum in: *Ann Surg Oncol*. 2018 Jan 19;: PMID: 29270877.

- 26: Votanopoulos KI, Sugarbaker P, Deraco M, Morris D, Glehen O, Elias D, De Simone M, Robella M, Heyd B, **Kusamura S**, Baratti D, Chouliaras K, Russell G, Shen P, Levine EA; RENAPE Working Group. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. *Ann Surg Oncol*. 2018 Mar;25(3):667-673. doi: 10.1245/s10434-017-6293-5. Epub 2017 Dec 19. PMID: 29260418.
- 27: Baratti D, **Kusamura S**, Milione M, Bruno F, Guaglio M, Deraco M. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg Oncol*. 2018 Feb;25(2):404-413. doi: 10.1245/s10434-017-6252-1. Epub 2017 Nov 20. PMID: 29159742.
- 28: Baratti D, **Kusamura S**, Iusco D, Gimondi S, Pietrantonio F, Milione M, Guaglio M, Bonomi S, Grassi A, Virzi S, Leo E, Deraco M. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases. *Ann Surg Oncol*. 2017 Jan;24(1):167-175. doi: 10.1245/s10434-016-5488-5. Epub 2016 Aug 12. PMID: 27519353.
- 29: Verwaal VJ, Rau B, Jamali F, Gilly FN, de Hingh I, Takala H, Syk I, Pelz J, Mulsow J, van der Speeten K, **Shigeki K**, Iversen LH, Mohamed F, Glehen O, Younan R, Yarema R, Gonzalez-Moreno S, O'Dwyer S, Yonemura, Y, Sugarbaker P. Registries on peritoneal surface malignancies throughout the world, their use and their options. *Int J Hyperthermia*. 2017 Aug;33(5):528-533. doi: 10.1080/02656736.2017.1315178. PMID: 28540833.
- 30: **Kusamura S**, Sinukumar S, Baratti D, Guaglio M, Guadagni S, Deraco M (2017). Cytoreductive Surgery and HIPEC in the First-Line and Interval Time Points of Advanced Epithelial Ovarian Cancer. *INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY*, vol. 15, p. 11-20, ISSN: 2363-8397, doi: 10.1007/s40944-017-0148-7.
- 31: Baratti D, **Kusamura S**, Milione M, Pietrantonio F, Caporale M, Guaglio M, Deraco M. Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study. *Ann Surg Oncol*. 2016 Dec;23(13):4222-4230. doi: 10.1245/s10434-016-5350-9. Epub 2016 Jun 28. PMID: 27352203.
- 32: Pietrantonio F, Perrone F, Mennitto A, Gleeson EM, Milione M, Tamborini E, Busico A, Settanni G, Berenato R, Caporale M, Morano F, Bossi I, Pellegrinelli A, Di Bartolomeo M, de Braud F, Baratti D, Bowne WB, **Kusamura S**, Deraco M. Toward the molecular dissection of peritoneal pseudomyxoma. *Ann Oncol*. 2016 Nov;27(11):2097-2103. doi: 10.1093/annonc/mdw314. Epub 2016 Aug 8. PMID: 27502722.
- 33: Pietrantonio F, Berenato R, Maggi C, Caporale M, Milione M, Perrone F, Tamborini E, Baratti D, **Kusamura S**, Mariani L, Niger M, Mennitto A, Gloghini A, Bossi I, Settanni G, Busico A, Bagnoli PF, Di Bartolomeo M, Deraco M, de Braud F. GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. *J Transl Med*. 2016 May 6;14(1):125. doi: 10.1186/s12967-016-0877-x. PMID: 27154293; PMCID: PMC4859944.
- 34: Deraco M, **Kusamura S**, Baratti D. Comment on the review entitled "A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer" by Chiva LM and Gonzalez-Martin A. *Gynecol Oncol Rep*. 2015 Nov 28;15:7-8. doi: 10.1016/j.gore.2015.11.002. PMID: 26937478; PMCID: PMC4750010.
- 35: Baratti D, **Kusamura S**, Pietrantonio F, Guaglio M, Niger M, Deraco M. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review. *Crit Rev Oncol Hematol*. 2016 Apr;100:209-22. doi: 10.1016/j.critrevonc.2016.01.017. Epub 2016 Jan 22. PMID: 26867984.
- 36: Deraco M, **Kusamura S**, Corbellini C, Guaglio M, Paviglianiti C, Baratti D. Treatment principles for peritoneal surface malignancies. *Minerva Chir*. 2016 Apr;71(2):124-45. Epub 2016 Feb 5. PMID: 26847729.
- 37: **Kusamura S**, Torres Mesa PA, Cabras A, Baratti D, Deraco M. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). *Ann Surg Oncol*. 2016 May;23(5):1468-73. doi: 10.1245/s10434-015-4962-9. Epub 2015 Nov 16. PMID: 26572754.
- 38: **Kusamura S**, Baratti D, Hutanu I, Gavazzi C, Morelli D, Iusco DR, Grassi A, Bonomi S, Virzi S, Haeusler E, Deraco M. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). *Eur J Surg Oncol*. 2015 Aug;41(8):1097-105. doi: 10.1016/j.ejso.2015.04.005. Epub 2015 May 16. PMID: 26026742.



- 39: Deraco M, Cabras A, Baratti D, **Kusamura S**. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase II $\alpha$ , and Ki-67 in diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray. *Ann Surg Oncol*. 2015 Dec;22(13):4344-51. doi: 10.1245/s10434-015-4498-z. Epub 2015 Mar 17. PMID: 25777091.
- 40: Piccioni F, Casiraghi C, Fumagalli L, **Kusamura S**, Baratti D, Deraco M, Arienti F, Langer M. Epidural analgesia for cytoreductive surgery with peritonectomy and heated intraperitoneal chemotherapy. *Int J Surg*. 2015 Apr;16(Pt A):99-106. doi: 10.1016/j.ijso.2015.02.025. Epub 2015 Mar 11. PMID: 25771101.
- 41: Baratti D, **Kusamura S**, Guaglio M, Deraco M. Peritoneal metastases: challenges for the surgeon. *Minerva Chir*. 2015 Jun;70(3):195-215. Epub 2015 Mar 10. PMID: 25752673.
- 42: Baratti D, **Kusamura S**, Maggi C, de Braud F, Deraco M, Di Bartolomeo M, Pietrantonio F. In reply. *Oncologist*. 2015 Mar;20(3):e5. doi: 10.1634/theoncologist.2014-423. PMID: 25745055; PMCID: PMC4350808.
- 43: Colombo C, Baratti D, **Kusamura S**, Deraco M, Gronchi A. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) and isolated perfusion (ILP) interventions in sarcoma. *J Surg Oncol*. 2015 Apr;111(5):570-9. doi: 10.1002/jso.23808. Epub 2014 Oct 28. PMID: 25351775.
- 44: **Kusamura S**, Moran BJ, Sugarbaker PH, Levine EA, Elias D, Baratti D, Morris DL, Sardi A, Glehen O, Deraco M; Peritoneal Surface Oncology Group International (PSOGI). Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. *Br J Surg*. 2014 Dec;101(13):1758-65. doi: 10.1002/bjs.9674. Epub 2014 Oct 20. PMID: 25329419.
- 45: Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, **Kusamura S**, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spiliotis J, Torres-Melero J, Turaga K, Trout R. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. *J Surg Oncol*. 2014 Dec;110(7):779-85. doi: 10.1002/jso.23728. Epub 2014 Aug 2. PMID: 25088304.
- 46: Pietrantonio F, Maggi C, Fanetti G, Iacovelli R, Di Bartolomeo M, Ricchini F, Deraco M, Perrone F, Baratti D, **Kusamura S**, Tamborini E, Castano A, Consonni PV, Bossi I, Gavazzi C, Milione M, Pelosi G, de Braud F. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. *Oncologist*. 2014 Aug;19(8):845-50. doi: 10.1634/theoncologist.2014-0106. Epub 2014 Jun 20. PMID: 24951608; PMCID: PMC4122474.
- 47: Baratti D, **Kusamura S**, Iusco D, Bonomi S, Grassi A, Virzi S, Leo E, Deraco M. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients. *Dis Colon Rectum*. 2014 Jul;57(7):858-68. doi: 10.1097/DCR.000000000000149. PMID: 24901687.
- 48: Baratti D, **Kusamura S**, Deraco M. Colorectal Cancer Peritoneal Metastases: Second-look Laparotomy, Prophylactic HIPEC, or Both? *Ann Surg*. 2016 Jan;263(1):e5. doi: 10.1097/SLA.0000000000000773. PMID: 24887973.
- 49: Baratti D, **Kusamura S**, Deraco M. Carboplatin plus paclitaxel scheduling for advanced ovarian cancer. *Lancet Oncol*. 2014 Jun;15(7):e249. doi: 10.1016/S1470-2045(14)70197-4. PMID: 24872106.
- 50: Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, **Kusamura S**, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spiliotis J, Torres-Melero J, Turaga K, Trout R. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. *Ann Surg Oncol*. 2014 Dec;21(13):4195-201. doi: 10.1245/s10434-014-3798-z. Epub 2014 May 23. PMID: 24854493.
- 51: Baratti D, **Kusamura S**, Deraco M. Prevention and early treatment of peritoneal metastases from colorectal cancer: second-look laparotomy or prophylactic HIPEC? *J Surg Oncol*. 2014 Mar;109(3):225-6. doi: 10.1002/jso.23492. Epub 2014 Jan 22. PMID: 24452990.
- 52: Virzi S, Iusco D, Baratti D, Bonomi S, Grassi A, **Kusamura S**, Deraco M. Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases. *Tumori*. 2013 Sep-Oct;99(5):589-95. doi: 10.1700/1377.15307. PMID: 24362862.
- 53: Baratti D, **Kusamura S**, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). *Eur J Cancer*. 2013 Oct;49(15):3140-8. doi: 10.1016/j.ejca.2013.05.027. Epub 2013 Jul 4. PMID: 23831335.

- 54: **Kusamura S**, Hutanu I, Baratti D, Deraco M. Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei. *J Surg Oncol*. 2013 Jul;108(1):1-8. doi: 10.1002/jso.23329. Epub 2013 May 29. PMID: 23720095.
- 55: Deraco M, Baratti D, Hutanu I, Bertuli R, **Kusamura S**. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol*. 2013 Apr;20(4):1093-100. doi: 10.1245/s10434-012-2845-x. Epub 2013 Mar 2. PMID: 23456386.
- 56: **Kusamura S**, Baratti D, Virzi S, Bonomi S, Iusco DR, Grassi A, Hutanu I, Deraco M. Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres. *J Surg Oncol*. 2013 Mar;107(4):312-9. doi: 10.1002/jso.23231. Epub 2012 Aug 23. PMID: 22926536.
- 57: **Kusamura S**, Baratti D, Hutanu I, Rossi P, Deraco M. The importance of the learning curve and surveillance of surgical performance in peritoneal surface malignancy programs. *Surg Oncol Clin N Am*. 2012 Oct;21(4):559-76. doi: 10.1016/j.soc.2012.07.011. PMID: 23021716.
- 58: Ditto A, Martinelli F, Reato C, **Kusamura S**, Solima E, Fontanelli R, Haeusler E, Raspagliesi F. Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study. *Ann Surg Oncol*. 2012 Nov;19(12):3849-55. doi: 10.1245/s10434-012-2439-7. Epub 2012 Jun 16. PMID: 22707110.
- 59: Solima E, Martinelli F, Ditto A, Maccauro M, Carcangiu M, Mariani L, **Kusamura S**, Fontanelli R, Grijuela B, Raspagliesi F. Diagnostic accuracy of sentinel node in endometrial cancer by using hysteroscopic injection of radiolabeled tracer. *Gynecol Oncol*. 2012 Sep;126(3):419-23. doi: 10.1016/j.ygyno.2012.05.025. Epub 2012 May 30. PMID: 22659192.
- 60: Baratti D, Kusamura S, Mingrone E, Balestra MR, Laterza B, Deraco M. Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. *Ann Surg*. 2012 Aug;256(2):334-41. doi: 10.1097/SLA.0b013e31825704e3. PMID: 22580946.
- 61: Deraco M, Virzi S, Iusco DR, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Grassi A, Baratti D, **Kusamura S**. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. *BJOG*. 2012 Jun;119(7):800-9. doi: 10.1111/j.1471-0528.2011.03207.x. PMID: 22571746.
- 62: Baratti D, **Kusamura S**, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. *Ann Surg Oncol*. 2012 May;19(5):1416-24. doi: 10.1245/s10434-012-2237-2. PMID: 22302266.
- 63: **Kusamura S**, Baratti D, Deraco M. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. *Ann Surg*. 2012 Feb;255(2):348-56. doi: 10.1097/SLA.0b013e3182436c28. PMID: 22202584.
- 64: Deraco M, **Kusamura S**, Virzi S, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Iusco DR, Baratti D. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. *Gynecol Oncol*. 2011 Aug;122(2):215-20. doi: 10.1016/j.ygyno.2011.05.004. Epub 2011 Jun 12. PMID: 21665254.
- 65: Orsenigo E, **Kusamura S**, Staudacher C. Sentinel lymph node and prognostic factors in gastric cancer. *Surg Endosc*. 2011 Nov;25(11):3715-6. doi: 10.1007/s00464-011-1609-1. PMID: 21557000.
- 66: Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH; Peritoneal Surface Oncology Group. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database\*. *Cancer*. 2011 May 1;117(9):1855-63. doi: 10.1002/cncr.25640. Epub 2010 Nov 18. PMID: 21509762.
- 67: Baratti D, **Kusamura S**, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. *J Surg Oncol*. 2011 Jun;103(8):822-31. doi: 10.1002/jso.21787. Epub 2011 Jan 31. PMID: 21283990.
- 68: Deraco M, Baratti D, Cabras AD, Zaffaroni N, Perrone F, Villa R, Jocolle J, Balestra MR, **Kusamura S**, Laterza B, Pilotti S. Experience with peritoneal mesothelioma at the Milan National Cancer Institute. *World J Gastrointest Oncol*. 2010 Feb 15;2(2):76-84. doi: 10.4251/wjgo.v2.i2.76. PMID: 21160925; PMCID: PMC2999160.
- 69: Baratti D, **Kusamura S**, Laterza B, Balestra MR, Deraco M. Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *World J Gastrointest Oncol*. 2010 Jan 15;2(1):36-43. doi: 10.4251/wjgo.v2.i1.36. PMID: 21160815; PMCID: PMC2999156.

- 70: **Kusamura S**, Baratti D, Zaffaroni N, Villa R, Laterza B, Balestra MR, Deraco M. Pathophysiology and biology of peritoneal carcinomatosis. *World J Gastrointest Oncol.* 2010 Jan 15;2(1):12-8. doi: 10.4251/wjgo.v2.i1.12. PMID: 21160812; PMCID: PMC2999153.
- 71: Deraco M, Baratti D, Laterza B, Balestra MR, Mingrone E, Macri A, Virzi S, Puccio F, Ravenda PS, **Kusamura S**. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. *Eur J Surg Oncol.* 2011 Jan;37(1):4-9. doi:10.1016/j.ejso.2010.11.004. Epub 2010 Nov 26. PMID: 21112721.
- 72: Chua TC, Yan TD, Deraco M, Glehen O, Moran BJ, Sugarbaker PH; Peritoneal Surface Oncology Group. Multi-institutional experience of diffuse intra- abdominal multicystic peritoneal mesothelioma. *Br J Surg.* 2011 Jan;98(1):60-4. doi: 10.1002/bjs.7263. Epub 2010 Sep 24. PMID: 20872843.
- 73: Baratti D, Vaira M, **Kusamura S**, D'Amico S, Balestra MR, Cioppa T, Mingrone E, De Simone M, Deraco M. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). *Eur J Surg Oncol.* 2010 Nov;36(11):1047-53. doi: 10.1016/j.ejso.2010.08.130. Epub 2010 Sep 15. PMID: 20832234.
- 74: Baratti D, Pennacchioli E, **Kusamura S**, Fiore M, Balestra MR, Colombo C, Mingrone E, Gronchi A, Deraco M. Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? *Ann Surg Oncol.* 2010 Dec;17(12):3220-8. doi: 10.1245/s10434-010-1178-x. Epub 2010 Jun 29. Erratum in: *Ann Surg Oncol.* 2011 Dec;18 Suppl 3:S327. Alessandro, Gronchi [corrected to Gronchi, Alessandro]. PMID: 20585874.
- 75: Balestra MR, Baratti D, Crippa F, Laterza B, **Kusamura S**, Langer M, Deraco M. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in a patient with peritoneal mesothelioma and HIV infection. *Tumori.* 2010 Mar- Apr;96(2):340-4. PMID: 20572597.
- 76: Baratti D, Scivales A, Balestra MR, Ponzi P, Di Stasi F, **Kusamura S**, Laterza B, Deraco M. Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). *Eur J Surg Oncol.* 2010 May;36(5):463-9. doi: 10.1016/j.ejso.2010.03.005. Epub 2010 Apr 2. PMID:20363094.
- 77: Yan TD, Deraco M, Baratti D, **Kusamura S**, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. *J Clin Oncol.* 2009 Dec 20;27(36):6237-42. doi: 10.1200/JCO.2009.23.9640. Epub 2009 Nov 16. PMID: 19917862.
- 78: Baratti D, **Kusamura S**, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. *Ann Surg Oncol.* 2010 Jan;17(1):45-53. doi: 10.1245/s10434-009-0756-2. Epub 2009 Oct 24. PMID: 19856030.
- 79: Deraco M, Baratti D, **Kusamura S**, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. *J Surg Oncol.* 2009 Sep 15;100(4):321-8. doi: 10.1002/jso.21388. PMID: 19697439.
- 80: Ditto A, Martinelli F, Borreani C, **Kusamura S**, Hanozet F, Brunelli C, Rossi G, Solima E, Fontanelli R, Zanaboni F, Grijuela B, Raspagliesi F. Quality of life and sexual, bladder, and intestinal dysfunctions after class III nerve- sparing and class II radical hysterectomies: a questionnaire-based study. *Int J Gynecol Cancer.* 2009 Jul;19(5):953-7. doi: 10.1111/IGC.0b013e3181a2d171. PMID: 19574791.
- 81: Baratti D, **Kusamura S**, Deraco M. Circulating CA125 and diffuse malignant peritoneal mesothelioma. *Eur J Surg Oncol.* 2009 Nov;35(11):1198-9. doi: 10.1016/j.ejso.2009.04.007. Epub 2009 May 6. PMID: 19423265.
- 82: Laterza B, **Kusamura S**, Baratti D, Oliva GD, Deraco M. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. *In Vivo.* 2009 Jan-Feb;23(1):187-90. PMID: 19368148.
- 83: Laterza B, Baratti D, Cozzi G, **Kusamura S**, Oliva GD, Gavazzi C, Fumagalli L, Sironi A, Sabia D, Deraco M. Colobronchial fistula: an unusual complication after peritonectomy and hyperthermic intra-peritoneal chemotherapy (HIPEC). *In Vivo.* 2009 Jan-Feb;23(1):151-3. PMID: 19368141.
- 84: Baratti D, **Kusamura S**, Nonaka D, Cabras AD, Laterza B, Deraco M. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. *Ann Surg.* 2009 Feb;249(2):243-9. doi: 10.1097/SLA.0b013e31818e6c64. PMID: 19212177.

- 85: Baratti D, **Kusamura S**, Cabras AD, Dileo P, Laterza B, Deraco M. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). *Ann Surg Oncol*. 2009 Feb;16(2):463-72. doi: 10.1245/s10434-008-0219-1. Epub 2008 Dec 12. PMID: 19082859.
- 86: **Kusamura S**, Baratti D, Younan R, Deraco M. The Delphi approach to Attain consensus in methodology of local regional therapy for peritoneal surface malignancy. *J Surg Oncol*. 2008 Sep 15;98(4):217-9. doi: 10.1002/jso.21059. PMID: 18726907.
- 87: Rossi CR, Casali P, **Kusamura S**, Baratti D, Deraco M. The consensus statement on the locoregional treatment of abdominal sarcomatosis. *J Surg Oncol*. 2008 Sep 15;98(4):291-4. doi: 10.1002/jso.21067. PMID: 18726899.
- 88: Helm CW, Bristow RE, **Kusamura S**, Baratti D, Deraco M. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. *J Surg Oncol*. 2008 Sep 15;98(4):283-90. doi: 10.1002/jso.21083. PMID: 18726895.
- 89: Moran B, Baratti D, Yan TD, **Kusamura S**, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). *J Surg Oncol*. 2008 Sep 15;98(4):277-82. doi: 10.1002/jso.21054. PMID: 18726894.
- 90: Bozzetti F, Yu W, Baratti D, **Kusamura S**, Deraco M. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. *J Surg Oncol*. 2008 Sep 15;98(4):273-6. doi: 10.1002/jso.21052. PMID: 18726891.
- 91: Deraco M, Bartlett D, **Kusamura S**, Baratti D. Consensus statement on peritoneal mesothelioma. *J Surg Oncol*. 2008 Sep 15;98(4):268-72. doi: 10.1002/jso.21055. PMID: 18726890.
- 92: Esquivel J, Elias D, Baratti D, **Kusamura S**, Deraco M. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. *J Surg Oncol*. 2008 Sep 15;98(4):263-7. doi: 10.1002/jso.21053. PMID: 18726889.
- 93: Baratti D, **Kusamura S**, Deraco M. The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus. *J Surg Oncol*. 2008 Sep 15;98(4):258-62. doi: 10.1002/jso.21056. PMID: 18726888.
- 94: Younan R, **Kusamura S**, Baratti D, Cloutier AS, Deraco M. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. *J Surg Oncol*. 2008 Sep 15;98(4):253-7. doi: 10.1002/jso.21057. PMID: 18726887.
- 95: **Kusamura S**, Dominique E, Baratti D, Younan R, Deraco M. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. *J Surg Oncol*. 2008 Sep 15;98(4):247-52. doi: 10.1002/jso.21051. PMID: 18726886.
- 96: Glehen O, Cotte E, **Kusamura S**, Deraco M, Baratti D, Passot G, Beaujard AC, Noel GF. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. *J Surg Oncol*. 2008 Sep 15;98(4):242-6. doi: 10.1002/jso.21061. PMID: 18726885.
- 97: González-Moreno S, **Kusamura S**, Baratti D, Deraco M. Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. *J Surg Oncol*. 2008 Sep 15;98(4):237-41. doi: 10.1002/jso.21072. PMID: 18726884.
- 98: **Kusamura S**, O'Dwyer ST, Baratti D, Younan R, Deraco M. Technical aspects of cytoreductive surgery. *J Surg Oncol*. 2008 Sep 15;98(4):232-6. doi: 10.1002/jso.21058. PMID: 18726883.
- 99: Verwaal VJ, **Kusamura S**, Baratti D, Deraco M. The eligibility for local-regional treatment of peritoneal surface malignancy. *J Surg Oncol*. 2008 Sep 15;98(4):220-3. doi: 10.1002/jso.21060. PMID: 18726879.
- 100: Portilla AG, **Kusamura S**, Dario B, Marcello D. The intraoperative staging systems in the management of peritoneal surface malignancy. *J Surg Oncol*. 2008 Sep 15;98(4):228-31. doi: 10.1002/jso.21068. PMID: 18726882.
- 101: Villa R, Daidone MG, Motta R, Venturini L, De Marco C, Vannelli A, **Kusamura S**, Baratti D, Deraco M, Costa A, Reddel RR, Zaffaroni N. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. *Clin Cancer Res*. 2008 Jul 1;14(13):4134-40. doi: 10.1158/1078-0432.CCR-08-0099. PMID: 18593991.
- 102: Baratti D, **Kusamura S**, Sironi A, Cabras A, Fumagalli L, Laterza B, Deraco M. Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). *In Vivo*. 2008 Jan-Feb;22(1):153-7. PMID: 18396799.
- 103: Solima E, Brusati V, Ditto A, **Kusamura S**, Martinelli F, Hanozet F, Carcangiu ML, Maccauro M, Raspagliesi F. Hysteroscopy in endometrial cancer: new methods to evaluate transtubal leakage of saline distension medium. *Am J Obstet Gynecol*. 2008 Feb;198(2):214.e1-4. doi: 10.1016/j.ajog.2007.07.035. PMID: 18226628.

- 104: Deraco M, Laterza B, **Kusamura S**, Baratti D. Trattamento innovativo delle neoplasie peritoneali. Una review [Updated treatment of peritoneal carcinomas: a review]. *Minerva Chir.* 2007 Dec;62(6):459-76. Italian. PMID: 18091656.
- 105: Baratti D, **Kusamura S**, Nonaka D, Langer M, Andreola S, Favaro M, Gavazzi C, Laterza B, Deraco M. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). *Ann Surg Oncol.* 2008 Feb;15(2):526-34. doi: 10.1245/s10434-007-9691-2. Epub 2007 Nov 28. PMID: 18043976.
- 106: Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, Erdas R, Cabras A, **Kusamura S**, Baratti D, Deraco M, Daidone MG. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. *Cell Oncol.* 2007;29(6):453-66. doi: 10.1155/2007/456839. PMID: 18032822; PMCID: PMC4618413.
- 107: **Kusamura S**, Baratti D, Antonucci A, Younan R, Laterza B, Oliva GD, Gavazzi C, Deraco M. Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol.* 2007 Dec;14(12):3443-52. doi: 10.1245/s10434-007-9551-0. Epub 2007 Oct 2. PMID: 17909918.
- 108: Raspagliesi F, Ditto A, Hanozet F, Martinelli F, Solima E, Zanaboni F, **Kusamura S**, Fontanelli R. Nerve-sparing radical hysterectomy in cervical cancer: evolution of concepts. *Gynecol Oncol.* 2007 Oct;107(1 Suppl 1):S119-21. doi: 10.1016/j.ygyno.2007.07.020. Epub 2007 Aug 28. PMID: 17727932.
- 109: Baratti D, **Kusamura S**, Nonaka D, Oliva GD, Laterza B, Deraco M. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). *Ann Surg Oncol.* 2007 Oct;14(10):2790-7. doi: 10.1245/s10434-007-9475-8. Epub 2007 Jul 28. PMID: 17661150.
- 110: Deraco M, Baratti D, **Kusamura S**. Morbidity and quality of life following cytoreduction and HIPEC. *Cancer Treat Res.* 2007;134:403-18. doi: 10.1007/978-0-387-48993-3\_26. PMID: 17633069.
- 111: **Kusamura S**, Baratti D, Younan R, Laterza B, Oliva GD, Costanzo P, Favaro M, Gavazzi C, Grosso F, Deraco M. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. *Ann Surg Oncol.* 2007 Sep;14(9):2550-8. doi: 10.1245/s10434-007-9429-1. Epub 2007 Jun 9. PMID: 17558537.
- 112: Baratti D, **Kusamura S**, Martinetti A, Seregini E, Laterza B, Oliva DG, Deraco M. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol.* 2007 Aug;14(8):2300-8. doi: 10.1245/s10434-007-9393-9. Epub 2007 May 18. PMID: 17510772.
- 113: Deraco M, Baratti D, Zaffaroni N, Cabras AD, **Kusamura S**. Advances in clinical research and management of diffuse peritoneal mesothelioma. *Recent Results Cancer Res.* 2007;169:137-55. doi: 10.1007/978-3-540-30760-0\_13. PMID: 17506257.
- 114: Deraco M, **Kusamura S**, Laterza B, Favaro M, Fumagalli L, Costanzo P, Baratti D. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center. *In Vivo.* 2006 Nov-Dec;20(6A):773-6. PMID: 17203766.
- 115: Baratti D, **Kusamura S**, Martinetti A, Seregini E, Oliva DG, Laterza B, Deraco M. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. *Ann Surg Oncol.* 2007 Feb;14(2):500-8. doi: 10.1245/s10434-006-9192-8. Epub 2006 Dec 6. PMID: 17151789.
- 116: Nonaka D, **Kusamura S**, Baratti D, Casali P, Younan R, Deraco M. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. *Histopathology.* 2006 Oct;49(4):381-7. doi: 10.1111/j.1365-2559.2006.02512.x. PMID: 16978201.
- 117: Raspagliesi F, Fontanelli R, Rossi G, Ditto A, Solima E, Hanozet F, **Kusamura S**. Photodynamic therapy using a methyl ester of 5-aminolevulinic acid in recurrent Paget's disease of the vulva: a pilot study. *Gynecol Oncol.* 2006 Nov;103(2):581-6. doi: 10.1016/j.ygyno.2006.04.009. Epub 2006 Jun 21. PMID: 16793128.
- 118: **Kusamura S**, Deraco M, Baratti D, Inglese MG, Costanzo P, Favaro M, Manzi R, Gavazzi C. Cytoreductive surgery followed by intra peritoneal hyperthermic perfusion in the treatment of peritoneal surface malignancies: morbidity and mortality with closed abdomen technique. *J Exp Clin Cancer Res.* 2003 Dec;22(4 Suppl):207-12. PMID: 16767933.
- 119: Deraco M, De Simone M, Rossi CR, Cavaliere F, Difilippo F, Scuderi S, Pilatti P, **Kusamura S**. An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma. *J Exp Clin Cancer Res.* 2003 Dec;22(4 Suppl):41-5. PMID: 16767905.

- 120:** Deraco M, De Simone M, Rossi CR, Cavaliere F, Di Filippo F, Vaira M, Piatti P, **Kusamura S**. An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with pseudomyxoma peritonei. *J Exp Clin Cancer Res*. 2003 Dec;22(4 Suppl):35-9. PMID: 16767904.
- 121:** Raspagliesi F, **Kusamura S**, Campos Torres JC, de Souza GA, Ditto A, Zanaboni F, Younan R, Baratti D, Mariani L, Laterza B, Deraco M. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. *Eur J Surg Oncol*. 2006 Aug;32(6):671-5. doi: 10.1016/j.ejso.2006.03.011. Epub 2006 Apr 18. PMID: 16621425.
- 122:** Raspagliesi F, Hanozet F, Ditto A, Solima E, Zanaboni F, Vecchione F, **Kusamura S**. Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva. *Gynecol Oncol*. 2006 Aug;102(2):333-7. doi: 10.1016/j.ygyno.2005.12.027. Epub 2006 Feb 7. PMID: 16466657.
- 123:** **Kusamura S**, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. *Cancer*. 2006 Mar 1;106(5):1144-53. doi: 10.1002/cncr.21708. PMID: 16456817.
- 124:** Raspagliesi F, Ditto A, Fontanelli R, Zanaboni F, Solima E, Spatti G, Hanozet F, Vecchione F, Rossi G, **Kusamura S**. Type II versus Type III nerve-sparing radical hysterectomy: comparison of lower urinary tract dysfunctions. *Gynecol Oncol*. 2006 Aug;102(2):256-62. doi: 10.1016/j.ygyno.2005.12.014. Epub 2006 Jan 30. PMID: 16445968.
- 125:** Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, Salvatore A, Cabras Ad AD, **Kusamura S**. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. *Ann Surg Oncol*. 2006 Feb;13(2):229-37. doi: 10.1245/ASO.2006.03.045. Epub 2006 Jan 18. PMID: 16444562.
- 126:** Nonaka D, **Kusamura S**, Baratti D, Casali P, Cabras AD, Younan R, Rosai J, Deraco M. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. *Cancer*. 2005 Nov 15;104(10):2181-8. doi: 10.1002/cncr.21239. PMID: 16206294.
- 127:** Younan R, **Kusamura S**, Baratti D, Oliva GD, Costanzo P, Favaro M, Gavazzi C, Deraco M. Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. *Ann Surg Oncol*. 2005 Nov;12(11):910-8. doi: 10.1245/ASO.2005.11.030. Epub 2005 Sep 21. PMID: 16177862.
- 128:** Raspagliesi F, Zanaboni F, Vecchione F, Hanozet F, Scollo P, Ditto A, Grijuela B, Fontanelli R, Solima E, Spatti G, Scibilia G, **Kusamura S**. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. *Oncology*. 2004;67(5-6):376-81. doi: 10.1159/000082921. PMID: 15713993.
- 129:** **Kusamura S**, Raspagliesi F, Baratti D, Gronchi A, Casali P, Deraco M. Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: a feasibility study. *J Chemother*. 2004 Nov;16 Suppl 5:19-22. doi: 10.1080/1120009x.2004.11782376. PMID: 15675470.
- 130:** Raspagliesi F, Ditto A, Quattrone P, Solima E, Fontanelli R, Dousias V, **Kusamura S**, Carcangiu ML. Prognostic factors in microinvasive cervical squamous cell cancer: long-term results. *Int J Gynecol Cancer*. 2005 Jan-Feb;15(1):88-93. doi: 10.1111/j.1048-891x.2005.15009.x. PMID: 15670302.
- 131:** Raspagliesi F, Ditto A, **Kusamura S**, Fontanelli R, Vecchione F, Maccauro M, Solima E. Hysteroscopic injection of tracers in sentinel node detection of endometrial cancer: a feasibility study. *Am J Obstet Gynecol*. 2004 Aug;191(2):435-9. doi: 10.1016/j.ajog.2004.03.008. PMID: 15343218.
- 132:** Rossi CR, Deraco M, De Simone M, Mocellin S, Pilati P, Foletto M, Cavaliere F, **Kusamura S**, Gronchi A, Lise M. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. *Cancer*. 2004 May 1;100(9):1943-50. doi: 10.1002/cncr.20192. PMID: 15112276.
- 133:** Raspagliesi F, Ditto A, Fontanelli R, Solima E, Hanozet F, Zanaboni F, **Kusamura S**. Nerve-sparing radical hysterectomy: a surgical technique for preserving the autonomic hypogastric nerve. *Gynecol Oncol*. 2004 May;93(2):307-14. doi: 10.1016/j.ygyno.2004.01.048. PMID: 15099938.
- 134:** Deraco M, Baratti D, Inglese MG, Allaria B, Andreola S, Gavazzi C, **Kusamura S**. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. *Ann Surg Oncol*. 2004 Apr;11(4):393-8. doi: 10.1245/ASO.2004.07.002. PMID: 15070599.

135: Raspagliesi F, Ditto A, **Kusamura S**, Fontanelli R, Spatti G, Solima E, Zanaboni F, Carcangiu ML. Nerve-sparing radical hysterectomy: a pilot study. *Tumori*. 2003 Sep-Oct;89(5):497-501. PMID: 14870771.

136: Deraco M, Raspagliesi F, **Kusamura S**. Management of peritoneal surface component of ovarian cancer. *Surg Oncol Clin N Am*. 2003 Jul;12(3):561-83. doi:10.1016/s1055-3207(03)00027-9. PMID: 14567018.

137: **Kusamura S**, Derchain S, Alvarenga M, Gomes CP, Syrjänen KJ, Andrade LA. Expression of p53, Allegati c-erbB-2, Ki-67, and CD34 in granulosa cell tumor of the ovary. *Int J Gynecol Cancer*. 2003 Jul-Aug;13(4):450-7. doi: 10.1046/j.1525-1438.2003.13327.x. PMID: 12911721.

138: Deraco M, **Kusamura S**, Baratti D, Casali P, Zaffaroni N. Mesotelioma peritoneale: risultati di una procedura complessa e aggressiva comprendente peritonectomia e chemio ipertermia intra peritoneale e prospettive derivanti dalla ricerca traslazionale [Peritoneal mesothelioma: results of a complicated and aggressive procedure incorporating peritonectomy and intraperitoneal hyperthermic chemotherapy, and prospects derived from bench-to-bedside research]. *Tumori*. 2003 Jul-Aug;89(4 Suppl):56-7. Italian. PMID: 12903546.

139: Deraco M, **Kusamura S**, Gronchi A. Chirurgia citoriduttiva (peritonectomia) e chemio ipertermia intra peritoneale: un approccio innovativo ed efficace nel trattamento dello pseudomixoma peritonei [Cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic chemotherapy: an innovative and effective approach to the treatment of pseudomyxoma peritonei]. *Tumori*. 2003 Jul-Aug;89(4 Suppl):54-5. Italian. PMID: 12903545.

140: Raspagliesi F, Ditto A, Cobellis L, Quattrone P, Fontanelli R, **Kusamura S**, Solima E. Gonadoblastoma in androgen insensitivity syndrome: a case report. *Tumori*. 2003 Mar-Apr;89(2):196-8. PMID: 12841671.


141: Deraco M, Casali P, Inglese MG, Baratti D, Pennacchioli E, Bertulli R, **Kusamura S**. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. *J Surg Oncol*. 2003 Jul;83(3):147-53. doi: 10.1002/jso.10255. PMID: 12827682.

142: Deraco M, Gronchi A, Mazzaferro V, Inglese MG, Pennacchioli E, **Kusamura S**, Rizzi M, Anselmi RA Jr, Vaglini M. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei. *Tumori*. 2002 Sep-Oct;88(5):370-5. PMID: 12487553.

143: Deraco M, Rossi CR, Pennacchioli E, Guadagni S, Somers DC, Santoro N, Raspagliesi F, **Kusamura S**, Vaglini M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. *Tumori*. 2001 May-Jun;87(3):120-6. PMID: 11504363.

144: **Kusamura S**, Teixeira LC, dos Santos MA, de Angelo Andrade LA, Campos Torres JC, Sagarra A, Deraco M, Derchain SF. Ovarian germ cell cancer: clinicopathologic analysis and outcome of 31 cases. *Tumori*. 2000 Nov-Dec;86(6):450-4. PMID: 11218184.

Milano, 05 agosto 2020



-----  
(Shigeki Kusamura)